ロード中...
Miliary tuberculosis developing during adalimumab treatment for Behçet’s disease with uveitis
Tumour necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine in non-infective uveitis (NIU). Adalimumab, an anti-TNF-α monoclonal antibody, is approved for the treatment of severe NIU by the European Medicines Agency. There is a recognised risk of serious infections, including tuberculosis...
保存先:
| 出版年: | BMJ Case Rep |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6301654/ https://ncbi.nlm.nih.gov/pubmed/30567192 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2018-226772 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|